<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148075">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02000687</url>
  </required_header>
  <id_info>
    <org_study_id>20080127</org_study_id>
    <nct_id>NCT02000687</nct_id>
  </id_info>
  <brief_title>Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss</brief_title>
  <official_title>Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rodolfo Alejandro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective, open label study in islet transplant recipients. After
      complete islet graft loss is determined, patient's maintenance immunosuppression (i.e.
      sirolimus, tacrolimus, MMF and/or Myfortic®) will be discontinued and they will be monitored
      for 10 years thereafter, for the appearance of allosensitization using panel reactive
      antibody (PRA) levels and monitor the persistence of elevated PRA levels. Primary objective
      is to determine the rate of allosensitization in patients 3 years after failed islet
      transplantation (i.e. stimulated c-peptide &lt;0.3mg/mL) and monitor the persistence of
      elevated PRA levels (≥ 20%) at year 3, 6, and 9. Timing, frequency and level of change in
      PRA will be monitored after all immunosuppression is discontinued.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>determine the rate of allosensitization in patients after failed islet transplantation</measure>
    <time_frame>10 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Islet Transplantation</condition>
  <condition>Allosensitization</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Ages 18-75 years old that received at least one IT. Participants will be obtained from the
        pool of islet transplant recipients transplanted at the Diabetes Research Institute at the
        University of Miami, Miller School of Medicine.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. History of at least one islet alone transplant (ie islet transplant in the absence of
        any other organ transplant).

        Exclusion Criteria:

          1. Inability to provide written informed consent.

          2. Mentally unstable and/or unable to comply with the procedures of the study protocol.

          3. History of any solid organ transplant.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodolfo Alejandro, MD</last_name>
      <phone>305-243-5321</phone>
      <email>islet@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Rodolfo Alejandro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.diabetesresearch.org/diabetes-clinical-trials</url>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Rodolfo Alejandro</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
